Denali Therapeutics (Denali Therapeutics) Cost of Goods Sold

: $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Denali Therapeutics's cost of goods sold for the three months ended in Dec. 2023 was $0.0 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Denali Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.

Denali Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Denali Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cost of Goods Sold

Denali Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cost of Goods Sold																-	-	-	-	-

Denali Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Denali Therapeutics (NAS:DNLI) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Denali Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	(Revenue	-	Cost of Goods Sold)	/	Revenue
	=	(0	-	0)	/	0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Denali Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.

Denali Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (Denali Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Cost of Goods Sold

Comparable Companies

Traded in Other Exchanges

4DN:Germany

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Executives

Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho	officer: Chief Medical Officer	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts	director, officer: President and CEO	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes	officer: CFO and Treasurer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth	officer: COO and Secretary	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne	director	1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris	director	60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton	10 percent owner	201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631